文摘
Tibolone is a synthetic steroid that is prescribed to postmenopausal women for relief of climacteric symptoms and prevention of osteoporosis. It has been reported to be metabolized in a tissue-selective manner to three steroids that collectively have weak estrogenic, progestogenic, and androgenic activities. Recently, a new tibolone metabolite, 7α-methyl-17α-ethynyl-17β-estradiol (7α-Me-EE2), was identified in women. In this report, we describe the pre-clinical estrogenic activities of this metabolite and compare these effects to those obtained with 17α-ethynyl-17β-estradiol (EE2) and 17β-estradiol (E2). In an in vitro ligand-binding assay, 7α-Me-EE2 bound to both human estrogen receptor (ER)-α and -β with IC<sub>50sub>’s of 1.2 and 3.0nM, respectively. Using MCF-7 human breast cancer cells that express high levels of ER-α, 7α-Me-EE2 transactivated an estrogen response element (ERE)-tk-luciferase reporter gene construct with an EC<sub>50sub> of 0.021nM. Likewise, 7α-Me-EE2 stimulated MCF-7 breast cancer cell proliferation with an EC<sub>50sub> of 0.002nM. In immature female rats, subcutaneous (s.c.) administration of 7α-Me-EE2 stimulated uterine wet weight gain with an ED<sub>50sub> of 0.2μg/kg. Moreover, 7α-Me-EE2 induced uterine complement component C3 gene expression, an estrogenic marker of epithelial cell stimulation, with an ED<sub>50sub> of 0.5μg/kg. When compared to EE2 and E2, 7α-Me-EE2 exhibited equivalent or greater potencies and efficacies in these assays. In summary, these results indicate that 7α-Me-EE2 is a very potent estrogen. This steroid appears to be the most potent estrogenic metabolite of tibolone identified to date, and additional studies are, therefore, warranted regarding the role of this metabolite in the biological actions of the drug.
